IN2012DN05143A - - Google Patents

Download PDF

Info

Publication number
IN2012DN05143A
IN2012DN05143A IN5143DEN2012A IN2012DN05143A IN 2012DN05143 A IN2012DN05143 A IN 2012DN05143A IN 5143DEN2012 A IN5143DEN2012 A IN 5143DEN2012A IN 2012DN05143 A IN2012DN05143 A IN 2012DN05143A
Authority
IN
India
Prior art keywords
present
glioma
tbs40
nfl
peptide
Prior art date
Application number
Other languages
English (en)
Inventor
Joel Eyer
Alan Peterson
Julien Balzeau
Raphael Berges
Original Assignee
Univ Angers
Inst Nat Sante Rech Med
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Angers, Inst Nat Sante Rech Med, Univ Mcgill filed Critical Univ Angers
Publication of IN2012DN05143A publication Critical patent/IN2012DN05143A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039Coumarin dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056Peptides, proteins, polyamino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IN5143DEN2012 2009-12-14 2010-12-14 IN2012DN05143A (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28620709P 2009-12-14 2009-12-14
EP09306227A EP2332560A1 (de) 2009-12-14 2009-12-14 Verwendung von Neurofilamentpeptid zur Behandlung von Gliomen
PCT/EP2010/069663 WO2011073207A1 (en) 2009-12-14 2010-12-14 Use of a neurofilament peptide for the treatment of glioma

Publications (1)

Publication Number Publication Date
IN2012DN05143A true IN2012DN05143A (de) 2015-10-23

Family

ID=42133636

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5143DEN2012 IN2012DN05143A (de) 2009-12-14 2010-12-14

Country Status (7)

Country Link
US (2) US9446092B2 (de)
EP (2) EP2332560A1 (de)
JP (1) JP5806679B2 (de)
CN (1) CN102821777B (de)
CA (1) CA2784091C (de)
IN (1) IN2012DN05143A (de)
WO (1) WO2011073207A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2869909B1 (fr) * 2004-05-04 2007-12-21 Univ Angers Peptide capable d'inhiber la polymerisation de la tubuline et son utilisation pour inhiber la proliferation cellulaire
EP2959913A1 (de) * 2014-06-23 2015-12-30 Universite D'angers Verwendung von Neurofilamentpeptid zum Targeting von neuralen Stammzellen
JP6612063B2 (ja) * 2015-06-11 2019-11-27 国立大学法人滋賀医科大学 悪性神経膠腫分子標的ペプチド
US10183058B2 (en) * 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10550388B2 (en) * 2017-08-15 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Targeting pleiotrophin signaling to limit high-grade glioma invasion
CN110133288A (zh) * 2018-03-13 2019-08-16 首都医科大学附属北京地坛医院 神经丝蛋白轻链在梅毒血液检测中的应用
EP3863686A1 (de) * 2018-10-12 2021-08-18 Advanced Accelerator Applications International S.A. Pharmazeutische zusammensetzung mit einem radiomarkierten gprp-antagonisten und einem tensid
CN112824427B (zh) * 2019-11-18 2022-06-24 杨小骏 一种抑制胶质瘤的短肽及其应用
EP4593865B1 (de) * 2022-09-30 2026-05-06 Gliocure Pharmazeutische zusammensetzung mit nfl-tbs40-63 peptid, varianten oder salzen davon und alanin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2869909B1 (fr) * 2004-05-04 2007-12-21 Univ Angers Peptide capable d'inhiber la polymerisation de la tubuline et son utilisation pour inhiber la proliferation cellulaire

Also Published As

Publication number Publication date
US9446092B2 (en) 2016-09-20
CN102821777B (zh) 2014-12-17
JP2013513646A (ja) 2013-04-22
WO2011073207A1 (en) 2011-06-23
CN102821777A (zh) 2012-12-12
EP2512499B1 (de) 2015-09-16
EP2332560A1 (de) 2011-06-15
US20130004429A1 (en) 2013-01-03
CA2784091C (en) 2020-08-11
JP5806679B2 (ja) 2015-11-10
US20170000846A1 (en) 2017-01-05
EP2512499A1 (de) 2012-10-24
CA2784091A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
SA515360657B1 (ar) مثبطات ديميثيلاز هيستون
EA201291107A1 (ru) Соединения, ингибирующие металлоферменты
MX2009013990A (es) Metodos para tratar enfermedades y trastornos mediados por serotonina.
TN2009000323A1 (en) Modulators of sclerostin binding partners for treating bone-related disorders
NO20076401L (no) Diarylhydantoinforbindelser
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
UA102250C2 (ru) Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2008005954A3 (en) Tryphostin-analogs for the treatment of cell proliferative diseases
TN2011000221A1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
MY153766A (en) Derivatised proline containing peptide organic compounds as protease inhibitors
MX2009008461A (es) Variantes geneticas que contribuyen a riesgo de cancer de prostata.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2010008021A (es) Nuevos derivados de n-(2-amino-fenil)-amida.
UA102115C2 (ru) Дизамещенные фталазиновые антагонисты сигнального пути hedgehog
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MX349550B (es) 1,7-diazacarbazoles y metodos de uso.
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
MY150600A (en) Use of opioid antagonists for treating urinary retention
GEP20125647B (en) Kinesin inhibitors as cancer therapeutics
WO2008144507A3 (en) Spirooxindole inhibitors of aurora kinase
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
IN2013MN01188A (de)
MX2007016469A (es) Metodos de tratamiento utilizando ansamicinas de hidroquinona.